相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
M. Lebwohl et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study
D. Thaci et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
Richard G. Langley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
Psoriasis and the Risk of Diabetes and Hypertension
Abrar A. Qureshi et al.
ARCHIVES OF DERMATOLOGY (2009)
Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis
Kristian Reich et al.
DERMATOLOGY (2009)
The Burden of Psoriasis in Canada: Insights from the pSoriasis Knowledge IN Canada (SKIN) Survey
Charles W. Lynde et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2009)
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis
Paolo Gisondi et al.
JOURNAL OF HEPATOLOGY (2009)
Disease severity, quality of life and health care in plaque-type psoriasis: A multicenter cross-sectional study in Germany
M. Augustin et al.
DERMATOLOGY (2008)
Association between psoriasis and the metabolic syndrome
A. D. Cohen et al.
DERMATOLOGY (2008)
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
Alexa B. Kimball et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis
D. Revicki et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study
P. Gisondi et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis
Dennis A. Revicki et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2007)
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis
Dorothea M. Sommer et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2006)
Prevalence of cardiovascular risk factors in patients with psoriasis
Andrea L. Neimann et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study
Richard Shikiar et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
Clinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis:: results from a phase III international randomized, placebo-controlled trial
L. Dubertret et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva
Jean-Paul Ortonne et al.
BMC DERMATOLOGY (2005)
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial
GG Krueger et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial
SR Feldman et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
Translating the science of quality of life into practice: What do dermatology life quality index scores mean?
Y Hongbo et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
A Menter et al.
ARCHIVES OF DERMATOLOGY (2005)
Efalizumab for patients with moderate to severe plaque psoriasis - A randomized controlled trial
KB Gordon et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Etanercept as monotherapy in patients with psoriasis
CL Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Psychiatric and psychological co-morbidity in patients with dermatologic disorders - Epidemiology and management
MA Gupta et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2003)
Effects of alefacept on health-related quality of life in patients with psoriasis - Results from a randomized, placebo-controlled phase II trial
CN Ellis et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2003)
Quantifying the harmful effect of psoriasis on health-related quality of life
SC Weiss et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
CN Ellis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin
CR Touw et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)
The contribution of perceptions of stigmatisation to disability in patients with psoriasis
HL Richards et al.
JOURNAL OF PSYCHOSOMATIC RESEARCH (2001)
The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization
SB Perrott et al.
PHYSIOLOGY & BEHAVIOR (2000)
分享论文
